\-\ Texto\\:\\ \ \(0\)\
\-\ in\\ film\\ 1\\ the\\ gallbladder\\ \\(gb\\)\\ wall\\ is\\ markedly\\ thickened\\ \\(1\\.7\\ cm\\)\\,\\ with\\ a\\ lamellated\\ or\\ striated\\ appearance\\.\\ \\ ascites\\ is\\ present\\.\\ \\ portal\\ venous\\ flow\\ \\(not\\ shown\\)\\ is\\ hepatopetal\\,\\ normal\\ in\\ direction\\.\\ \\ one\\ day\\ later\\ \\(film\\ 2\\)\\,\\ the\\ gb\\ wall\\ thickening\\ has\\ increased\\ to\\ the\\ point\\ \\(2\\.3\\ cm\\)\\ that\\ the\\ lumen\\ is\\ now\\ obliterated\\.\\ \\ portal\\ venous\\ flow\\ \\(film\\ 3\\)\\ has\\ reversed\\ and\\ is\\ now\\ hepatofugal\\.\ \(0\)\
\-\ gallbladder\\ wall\\ thickening\\,\\ secondary\\ to\\ portal\\ venous\\ hypertension\\ from\\ hepatic\\ venocclusive\\ disease\\ \\(after\\ bone\\ marrow\\ transplant\\)\ \(0\)\
\-\ this\\ is\\ a\\ 39\\-year\\-old\\ female\\ five\\ and\\ six\\ days\\ after\\ bone\\ marrow\\ transplant\\ for\\ aplastic\\ anemia\\.\\ \\ she\\ had\\ received\\ chemotherapy\\ and\\ total\\ lymphoid\\ radiation\\ prior\\ to\\ the\\ transplant\\.\\ \\ right\\ upper\\ quadrant\\ pain\\ and\\ tenderness\\ have\\ been\\ increasing\\ for\\ several\\ days\\.\\ \\ two\\ ultrasound\\ examinations\\ are\\ performed\\,\\ the\\ initial\\ one\\ at\\ 5\\ days\\ \\(film\\ 1\\)\\ and\\ the\\ follow\\-up\\ at\\ 6\\ days\\ \\(films\\ 2\\ and\\ 3\\)\\.\ \(0\)\
\-\ gb\\ wall\\ thickening\\ is\\ a\\ non\\-specific\\ finding\\ and\\ can\\ be\\ seen\\ with\\ both\\ intrinsic\\ and\\ extrinsic\\ disease\\ processes\\.\\ \\ acute\\ and\\ chronic\\ cholecystitis\\ are\\ the\\ most\\ common\\ intrinsic\\ causes\\ of\\ gb\\ wall\\ thickening\\ and\\ the\\ degree\\ of\\ thickening\\ can\\ be\\ marked\\.\\ \\ a\\ striated\\ appearance\\ of\\ the\\ wall\\ from\\ alternating\\ hyperechoic\\ and\\ anechoic\\ regions\\ has\\ been\\ shown\\ to\\ occur\\ more\\ frequently\\ in\\ acute\\ cholecystitis\\ but\\ can\\ also\\ be\\ seen\\ with\\ extrinsic\\ disease\\,\\ as\\ shown\\ in\\ this\\ case\\.\\ \\ even\\ though\\ stones\\ and\\ sludge\\ are\\ often\\ present\\,\\ especially\\ with\\ chronic\\ cholecystitis\\,\\ they\\ can\\ be\\ absent\\.\\ \\ pericholecystic\\ fluid\\ and\\ ascites\\ are\\ significantly\\ associated\\ with\\ perforation\\ when\\ acute\\ cholecystitis\\ is\\ present\\,\\ but\\ these\\ findings\\ may\\ also\\ occur\\ with\\ extrinsic\\ disease\\.\\ \\ when\\ bright\\ hyperechoic\\ intramural\\ foci\\ are\\ seen\\,\\ emphysematous\\ and\\ gangrenous\\ cholecystitis\\ should\\ be\\ considered\\,\\ but\\ again\\,\\ these\\ findings\\ are\\ non\\-specific\\.\\ \\ the\\ clinical\\ situation\\ is\\ often\\ very\\ helpful\\ in\\ determining\\ the\\ significance\\ of\\ these\\ findings\\.\\ \\ other\\ intrinsic\\ causes\\ of\\ gb\\ wall\\ thickening\\ include\\ adenomyomatosis\\ and\\ both\\ primary\\ and\\ metastatic\\ malignancy\\.\\ \\ gb\\ wall\\ thickening\\ can\\ be\\ diffuse\\,\\ focal\\,\\ or\\ even\\ circumferential\\ with\\ adenomyomatosis\\,\\ whereas\\ malignancy\\ is\\ usually\\ focal\\.\\ \\ malignant\\ changes\\ can\\ extend\\ intraluminally\\ or\\ extrinsically\\ as\\ well\\.\ \(0\)\
\-\ on\\ occasion\\,\\ if\\ the\\ patient\\ has\\ eaten\\ prior\\ to\\ the\\ ultrasound\\ study\\,\\ the\\ gb\\ may\\ be\\ normally\\ contracted\\ and\\ have\\ thick\\ walls\\.\\ \\ the\\ wall\\ usually\\ has\\ three\\ layers\\.\\ \\ \ \(0\)\
\-\ extrinsic\\ causes\\ of\\ gb\\ wall\\ thickening\\ are\\ numerous\\ and\\ include\\ aids\\,\\ hepatitis\\,\\ sepsis\\,\\ hypoalbuminemia\\,\\ congestive\\ heart\\ failure\\,\\ amyloidosis\\,\\ lymphatic\\ obstruction\\,\\ and\\ portal\\ hypertension\\ from\\ any\\ cause\\.\\ \\ ascites\\ has\\ been\\ associated\\ with\\ gb\\ wall\\ thickening\\.\\ \\ while\\ this\\ may\\ be\\ technical\\,\\ related\\ to\\ beam\\ spreading\\ artifact\\,\\ it\\ is\\ more\\ commonly\\ associated\\ with\\ hypoalbuminemia\\ and\\/or\\ portal\\ hypertension\\.\ \(0\)\
\-\ gb\\ wall\\ thickening\\ in\\ aids\\ has\\ been\\ associated\\ with\\ cytomegalic\\ virus\\ \\(cmv\\)\\,\\ cryptosporidium\\,\\ and\\ mycobacterium\\ infections\\.\\ \\ intrinsic\\ inflammatory\\ cell\\ infiltrate\\ has\\ been\\ documented\\,\\ but\\ many\\ cases\\ are\\ likely\\ to\\ be\\ secondary\\ to\\ primary\\ liver\\ involvement\\,\\ cholangitis\\,\\ or\\ more\\ diffuse\\ abdominal\\ infection\\.\ \(0\)\
\-\ hypoalbuminemia\\ has\\ been\\ well\\ documented\\ as\\ a\\ cause\\ of\\ gb\\ wall\\ thickening\\,\\ but\\ values\\ \\<2\\.5\\ g\\/dl\\ are\\ usually\\ necessary\\.\\ \\ malignant\\ ascites\\ has\\ not\\ been\\ associated\\ with\\ gb\\ wall\\ thickening\\,\\ except\\ when\\ the\\ albumin\\ level\\ is\\ low\\.\ \(0\)\
\-\ portal\\ hypertension\\ with\\ or\\ without\\ hypoalbuminemia\\ is\\ commonly\\ the\\ cause\\ of\\ gb\\ wall\\ thickening\\ most\\ often\\ associated\\ with\\ cirrhosis\\.\\ \\ the\\ findings\\ in\\ this\\ patient\\ are\\ of\\ acute\\ and\\ fulminant\\ portal\\ hypertension\\ from\\ hepatic\\ venocclusive\\ disease\\.\\ \\ the\\ portal\\ hypertension\\ develops\\ because\\ of\\ occlusion\\ of\\ the\\ venous\\ outflow\\ at\\ the\\ level\\ of\\ the\\ terminal\\ hepatic\\ venules\\ and\\ sublobular\\ veins\\.\\ \\ since\\ the\\ major\\ hepatic\\ veins\\ are\\ not\\ involved\\,\\ this\\ distinguishes\\ this\\ entity\\ from\\ the\\ classic\\ budd\\-chiari\\ syndrome\\,\\ even\\ though\\ both\\ may\\ cause\\ acute\\ portal\\ hypertension\\.\\ \\ it\\ is\\ believed\\ the\\ chemotherapy\\ and\\ radiation\\ directly\\ damage\\ the\\ venules\\ as\\ well\\ as\\ the\\ hepatocytes\\.\\ \\ further\\ damage\\ to\\ the\\ hepatocytes\\ occurs\\ from\\ the\\ congestion\\ and\\ hypoxia\\.\\ \\ graft\\-versus\\-host\\ disease\\ may\\ also\\ cause\\ portal\\ hypertension\\ in\\ bone\\ marrow\\ transplant\\ patients\\,\\ but\\ the\\ development\\ is\\ much\\ more\\ chronic\\ and\\ occurs\\ well\\ after\\ the\\ onset\\ of\\ disease\\.\ \(0\)\
\-\ marked\\ gb\\ wall\\ thickening\\ \\(\\>1\\.0\\ cm\\)\\ is\\ most\\ commonly\\ found\\ with\\ acute\\ cholecystitis\\,\\ hepatitis\\,\\ and\\ hepatic\\ venous\\ occlusion\\.\\ \\ the\\ striated\\ appearance\\ in\\ the\\ gb\\ wall\\ may\\ be\\ related\\ pathologically\\ to\\ hemorrhagic\\ edema\\.\\ \\ as\\ mentioned\\ previously\\,\\ this\\ finding\\ has\\ also\\ been\\ significantly\\ associated\\ with\\ acute\\ cholecystitis\\.\\ \\ the\\ clinical\\ setting\\ and\\ correlation\\ with\\ other\\ findings\\ should\\ help\\ determine\\ the\\ value\\ of\\ this\\ finding\\ for\\ a\\ given\\ patient\\.\\ \\ as\\ much\\ of\\ this\\ discussion\\ has\\ focused\\ on\\ hepatic\\ venocclusive\\ disease\\,\\ it\\ should\\ be\\ emphasized\\ that\\ hepatic\\ venocclusive\\ disease\\ is\\ rare\\ except\\ in\\ a\\ small\\ subset\\ of\\ patients\\.\\ \\ acute\\ cholecystitis\\,\\ however\\,\\ is\\ common\\.\ \(0\)\
\-\ to\\ determine\\ the\\ direction\\ of\\ flow\\ with\\ duplex\\ doppler\\,\\ the\\ angle\\ of\\ the\\ transducer\\,\\ the\\ angle\\ of\\ the\\ vessel\\ being\\ sampled\\,\\ and\\ the\\ relationship\\ of\\ the\\ spectral\\ tracing\\ to\\ the\\ baseline\\ are\\ the\\ key\\ considerations\\.\\ \\ flow\\ in\\ the\\ vessel\\ toward\\ the\\ transducer\\ registers\\ the\\ spectral\\ tracing\\ above\\ the\\ baseline\\,\\ whereas\\ flow\\ away\\ from\\ the\\ transducer\\ registers\\ below\\ the\\ baseline\\ \\(unless\\ manually\\ inverted\\)\\.\\ \\ in\\ this\\ patient\\,\\ the\\ spectral\\ tracing\\ from\\ the\\ portal\\ vein\\ is\\ below\\ the\\ baseline\\ on\\ day\\ 6\\ \\(film\\ 3\\)\\.\\ \\ the\\ transducer\\ angles\\ from\\ the\\ patient\\'s\\ right\\ to\\ left\\,\\ and\\ the\\ spectral\\ tracing\\ registers\\ below\\ the\\ baseline\\,\\ indicating\\ flow\\ away\\ from\\ the\\ transducer\\,\\ right\\ to\\ left\\,\\ or\\ abnormal\\ hepatofugal\\ flow\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ gb\\:\\ 0\\.4182075708157874\ \(0\)\
\-\ the\\:\\ 0\\.25822640694258664\ \(0\)\
\-\ portal\\:\\ 0\\.23089901850049846\ \(0\)\
\-\ wall\\:\\ 0\\.2268307129473652\ \(0\)\
\-\ thickening\\:\\ 0\\.2089132008492529\ \(0\)\
\-\ cholecystitis\\:\\ 0\\.16913305278610688\ \(0\)\
\-\ transducer\\:\\ 0\\.14647241187101534\ \(0\)\
\-\ venocclusive\\:\\ 0\\.14031188121935628\ \(0\)\
\-\ tracing\\:\\ 0\\.14031188121935628\ \(0\)\
\-\ and\\:\\ 0\\.135974603756689\ \(0\)\
\-\ hypertension\\:\\ 0\\.1342631732207086\ \(0\)\
\-\ hypoalbuminemia\\:\\ 0\\.1262185735209465\ \(0\)\
\-\ spectral\\:\\ 0\\.1262185735209465\ \(0\)\
\-\ hepatic\\:\\ 0\\.1222724505735546\ \(0\)\
\-\ has\\:\\ 0\\.1202282446666823\ \(0\)\
\-\ baseline\\:\\ 0\\.11596137144598419\ \(0\)\
\-\ is\\:\\ 0\\.11413109622215016\ \(0\)\
\-\ intrinsic\\:\\ 0\\.10932100980360408\ \(0\)\
\-\ registers\\:\\ 0\\.1052339109145172\ \(0\)\
\-\ flow\\:\\ 0\\.10226929037611962\ \(0\)\
\-\ been\\:\\ 0\\.10223410005778859\ \(0\)\
\-\ are\\:\\ 0\\.09987754179163884\ \(0\)\
\-\ be\\:\\ 0\\.09787725102552962\ \(0\)\
\-\ acute\\:\\ 0\\.09492561680399095\ \(0\)\
\-\ extrinsic\\:\\ 0\\.09462445516686754\ \(0\)\
\-\ ascites\\:\\ 0\\.09049833364673834\ \(0\)\
\-\ transplant\\:\\ 0\\.08774442407318478\ \(0\)\
\-\ from\\:\\ 0\\.08711436002797314\ \(0\)\
\-\ of\\:\\ 0\\.08584951909237017\ \(0\)\
\-\ disease\\:\\ 0\\.08286574864862345\ \(0\)\
\-\ striated\\:\\ 0\\.08278663283171751\ \(0\)\
\-\ film\\:\\ 0\\.08195494436442238\ \(0\)\
\-\ associated\\:\\ 0\\.08092772222583312\ \(0\)\
\-\ venous\\:\\ 0\\.07830116003805623\ \(0\)\
\-\ to\\:\\ 0\\.07676999283259535\ \(0\)\
\-\ this\\:\\ 0\\.07537074092211603\ \(0\)\
\-\ cause\\:\\ 0\\.07471385254830072\ \(0\)\
\-\ with\\:\\ 0\\.07301569203563539\ \(0\)\
\-\ can\\:\\ 0\\.06906304574986898\ \(0\)\
\-\ hepatofugal\\:\\ 0\\.06703774660707736\ \(0\)\
\-\ venules\\:\\ 0\\.06703774660707736\ \(0\)\
\-\ may\\:\\ 0\\.0662286594191046\ \(0\)\
\-\ in\\:\\ 0\\.06547896950303093\ \(0\)\
\-\ but\\:\\ 0\\.0650797366352777\ \(0\)\
\-\ hepatocytes\\:\\ 0\\.06310928676047325\ \(0\)\
\-\ as\\:\\ 0\\.06168294608944552\ \(0\)\
\-\ days\\:\\ 0\\.05554183773583358\ \(0\)\
\-\ even\\:\\ 0\\.05535236409746952\ \(0\)\
\-\ adenomyomatosis\\:\\ 0\\.05519108855447834\ \(0\)\
\-\ marrow\\:\\ 0\\.05468452122018167\ \(0\)\
\-\ below\\:\\ 0\\.05419056604720695\ \(0\)\
\-\ findings\\:\\ 0\\.054127669183454616\ \(0\)\
\-\ or\\:\\ 0\\.05341424670799597\ \(0\)\
\-\ shown\\:\\ 0\\.051010960309677535\ \(0\)\
\-\ causes\\:\\ 0\\.049722385645385996\ \(0\)\
\-\ commonly\\:\\ 0\\.04869133382276206\ \(0\)\
\-\ direction\\:\\ 0\\.04836736082596996\ \(0\)\
\-\ more\\:\\ 0\\.04817744960764678\ \(0\)\
\-\ aids\\:\\ 0\\.04771707961816167\ \(0\)\
\-\ documented\\:\\ 0\\.04692762681166564\ \(0\)\
\-\ whereas\\:\\ 0\\.04656134746051059\ \(0\)\
\-\ away\\:\\ 0\\.045556824355348954\ \(0\)\
\-\ hepatitis\\:\\ 0\\.04509983372996413\ \(0\)\
\-\ finding\\:\\ 0\\.04325348097375439\ \(0\)\
\-\ often\\:\\ 0\\.04293669349692025\ \(0\)\
\-\ should\\:\\ 0\\.04293669349692025\ \(0\)\
\-\ damage\\:\\ 0\\.04270476115261282\ \(0\)\
\-\ well\\:\\ 0\\.04248308691169245\ \(0\)\
\-\ usually\\:\\ 0\\.041425658231051786\ \(0\)\
\-\ also\\:\\ 0\\.041269357923107465\ \(0\)\
\-\ significantly\\:\\ 0\\.04123075960444016\ \(0\)\
\-\ except\\:\\ 0\\.04088113518706041\ \(0\)\
\-\ determine\\:\\ 0\\.04079615738690518\ \(0\)\
\-\ hyperechoic\\:\\ 0\\.040384807326725225\ \(0\)\
\-\ occlusion\\:\\ 0\\.040305113218062606\ \(0\)\
\-\ when\\:\\ 0\\.03974904190914747\ \(0\)\
\-\ appearance\\:\\ 0\\.03967030017680534\ \(0\)\
\-\ gallbladder\\:\\ 0\\.039199324986267055\ \(0\)\
\-\ chronic\\:\\ 0\\.0390589985393928\ \(0\)\
\-\ veins\\:\\ 0\\.03892945825595975\ \(0\)\
\-\ angle\\:\\ 0\\.038478844952994425\ \(0\)\
\-\ vessel\\:\\ 0\\.038478844952994425\ \(0\)\
\-\ though\\:\\ 0\\.03811256560183938\ \(0\)\
\-\ much\\:\\ 0\\.03799424922714662\ \(0\)\
\-\ cm\\:\\ 0\\.037791620713453475\ \(0\)\
\-\ these\\:\\ 0\\.0371591515152036\ \(0\)\
\-\ both\\:\\ 0\\.03669519009446783\ \(0\)\
\-\ bone\\:\\ 0\\.03590436855594934\ \(0\)\
\-\ patient\\:\\ 0\\.03567088702709177\ \(0\)\
\-\ extrinsically\\:\\ 0\\.03507797030483907\ \(0\)\
\-\ cytomegalic\\:\\ 0\\.03507797030483907\ \(0\)\
\-\ cryptosporidium\\:\\ 0\\.03507797030483907\ \(0\)\
\-\ sublobular\\:\\ 0\\.03507797030483907\ \(0\)\
\-\ occurs\\:\\ 0\\.03458799111122832\ \(0\)\
\-\ most\\:\\ 0\\.03424606534306864\ \(0\)\
\-\ present\\:\\ 0\\.03376584536865606\ \(0\)\
\-\ it\\:\\ 0\\.03368382437000146\ \(0\)\
\-\ aplastic\\:\\ 0\\.03351887330353868\ \(0\)\
\-\ related\\:\\ 0\\.03333815347752033\ \(0\)\
\-\ marked\\:\\ 0\\.03317958265007364\ \(0\)\
\-\ malignancy\\:\\ 0\\.032841825617185155\ \(0\)\
\-\ hepatopetal\\:\\ 0\\.03241267637680385\ \(0\)\
\-\ occur\\:\\ 0\\.0322633264657968\ \(0\)\
\-\ after\\:\\ 0\\.03192229254070643\ \(0\)\
\-\ intraluminally\\:\\ 0\\.03155464338023663\ \(0\)\
\-\ fulminant\\:\\ 0\\.03155464338023663\ \(0\)\
\-\ distinguishes\\:\\ 0\\.03155464338023663\ \(0\)\
\-\ malignant\\:\\ 0\\.031271323830997066\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.03114982979288657\ \(0\)\
\-\ seen\\:\\ 0\\.03097969287143129\ \(0\)\
\-\ lamellated\\:\\ 0\\.030853579375503464\ \(0\)\
\-\ gangrenous\\:\\ 0\\.030853579375503464\ \(0\)\
\-\ emphasized\\:\\ 0\\.030853579375503464\ \(0\)\
\-\ sampled\\:\\ 0\\.030853579375503464\ \(0\)\
\-\ subset\\:\\ 0\\.030260838205274383\ \(0\)\
\-\ manually\\:\\ 0\\.030260838205274383\ \(0\)\
\-\ now\\:\\ 0\\.03011388313570094\ \(0\)\
\-\ eaten\\:\\ 0\\.02929448237420307\ \(0\)\
\-\ contracted\\:\\ 0\\.02929448237420307\ \(0\)\
\-\ spreading\\:\\ 0\\.02929448237420307\ \(0\)\
\-\ radiation\\:\\ 0\\.029071185617834276\ \(0\)\
\-\ reversed\\:\\ 0\\.028522862145267266\ \(0\)\
\-\ occasion\\:\\ 0\\.028522862145267266\ \(0\)\
\-\ obliterated\\:\\ 0\\.02818828544746825\ \(0\)\
\-\ mycobacterium\\:\\ 0\\.02818828544746825\ \(0\)\
\-\ day\\:\\ 0\\.027943744403179635\ \(0\)\
\-\ clinical\\:\\ 0\\.027802054184392418\ \(0\)\
\-\ situation\\:\\ 0\\.02759554427723917\ \(0\)\
\-\ technical\\:\\ 0\\.02759554427723917\ \(0\)\
\-\ inverted\\:\\ 0\\.02759554427723917\ \(0\)\
\-\ diffuse\\:\\ 0\\.02751123776111472\ \(0\)\
\-\ ultrasound\\:\\ 0\\.02705915919899188\ \(0\)\
\-\ primary\\:\\ 0\\.026974648319249967\ \(0\)\
\-\ lymphoid\\:\\ 0\\.026848974341020192\ \(0\)\
\-\ alternating\\:\\ 0\\.026629188446167858\ \(0\)\
\-\ level\\:\\ 0\\.026499361272764976\ \(0\)\
\-\ angles\\:\\ 0\\.02642128882455937\ \(0\)\
\-\ focal\\:\\ 0\\.02624040035283882\ \(0\)\
\-\ include\\:\\ 0\\.026101603247719107\ \(0\)\
\-\ focused\\:\\ 0\\.026036447275938776\ \(0\)\
\-\ secondary\\:\\ 0\\.02600221042429\ \(0\)\
\-\ not\\:\\ 0\\.02597760440017297\ \(0\)\
\-\ beam\\:\\ 0\\.025686642018304433\ \(0\)\
\-\ outflow\\:\\ 0\\.025522991519433037\ \(0\)\
\-\ pathologically\\:\\ 0\\.025522991519433037\ \(0\)\
\-\ duplex\\:\\ 0\\.025522991519433037\ \(0\)\
\-\ determining\\:\\ 0\\.025366022527598966\ \(0\)\
\-\ cholangitis\\:\\ 0\\.025366022527598966\ \(0\)\
\-\ virus\\:\\ 0\\.02521521079301728\ \(0\)\
\-\ one\\:\\ 0\\.025117011446505938\ \(0\)\
\-\ lymphatic\\:\\ 0\\.02507009144486747\ \(0\)\
\-\ sludge\\:\\ 0\\.024930250349203955\ \(0\)\
\-\ common\\:\\ 0\\.02487869790073739\ \(0\)\
\-\ at\\:\\ 0\\.02485476515360993\ \(0\)\
\-\ albumin\\:\\ 0\\.0247953169840503\ \(0\)\
\-\ patients\\:\\ 0\\.0246786622007455\ \(0\)\
\-\ emphysematous\\:\\ 0\\.024664958522865807\ \(0\)\
\-\ significance\\:\\ 0\\.024664958522865807\ \(0\)\
\-\ prior\\:\\ 0\\.024544733344250877\ \(0\)\
\-\ pericholecystic\\:\\ 0\\.024538874888505688\ \(0\)\
\-\ cmv\\:\\ 0\\.024538874888505688\ \(0\)\
\-\ intramural\\:\\ 0\\.024416794592698216\ \(0\)\
\-\ layers\\:\\ 0\\.02418368041298498\ \(0\)\
\-\ amyloidosis\\:\\ 0\\.02418368041298498\ \(0\)\
\-\ hypoxia\\:\\ 0\\.02418368041298498\ \(0\)\
\-\ examinations\\:\\ 0\\.023963894518132647\ \(0\)\
\-\ anechoic\\:\\ 0\\.023963894518132647\ \(0\)\
\-\ sepsis\\:\\ 0\\.023963894518132647\ \(0\)\
\-\ congestive\\:\\ 0\\.023963894518132647\ \(0\)\
\-\ entity\\:\\ 0\\.023858539809080835\ \(0\)\
\-\ develops\\:\\ 0\\.023656113791716886\ \(0\)\
\-\ circumferential\\:\\ 0\\.023558761596130986\ \(0\)\
\-\ believed\\:\\ 0\\.02346381340583282\ \(0\)\
\-\ infiltrate\\:\\ 0\\.023280673730255295\ \(0\)\
\-\ relationship\\:\\ 0\\.023280673730255295\ \(0\)\
\-\ mentioned\\:\\ 0\\.02319227428919684\ \(0\)\
\-\ cirrhosis\\:\\ 0\\.023105861521565414\ \(0\)\
\-\ key\\:\\ 0\\.023105861521565414\ \(0\)\
\-\ other\\:\\ 0\\.02278183032264362\ \(0\)\
\-\ considerations\\:\\ 0\\.022700728599563753\ \(0\)\
\-\ terminal\\:\\ 0\\.022549916864982065\ \(0\)\
\-\ toward\\:\\ 0\\.022476672625058286\ \(0\)\
\-\ value\\:\\ 0\\.022334241292629606\ \(0\)\
\-\ have\\:\\ 0\\.021914927832700402\ \(0\)\
\-\ correlation\\:\\ 0\\.021873580960470474\ \(0\)\
\-\ right\\:\\ 0\\.021816539171283886\ \(0\)\
\-\ directly\\:\\ 0\\.02181205634660317\ \(0\)\
\-\ congestion\\:\\ 0\\.021691883868414835\ \(0\)\
\-\ processes\\:\\ 0\\.021575353546627138\ \(0\)\
\-\ unless\\:\\ 0\\.021575353546627138\ \(0\)\
\-\ artifact\\:\\ 0\\.02119324588104562\ \(0\)\
\-\ thick\\:\\ 0\\.020845700515531862\ \(0\)\
\-\ helpful\\:\\ 0\\.020798519477797605\ \(0\)\
\-\ indicating\\:\\ 0\\.020751910345520264\ \(0\)\
\-\ stones\\:\\ 0\\.02070585941986835\ \(0\)\
\-\ perforation\\:\\ 0\\.02070585941986835\ \(0\)\
\-\ walls\\:\\ 0\\.020570926054714698\ \(0\)\
\-\ setting\\:\\ 0\\.02039807869345259\ \(0\)\
\-\ extend\\:\\ 0\\.020232667971921713\ \(0\)\
\-\ values\\:\\ 0\\.020232667971921713\ \(0\)\
\-\ anemia\\:\\ 0\\.020152556609031303\ \(0\)\
\-\ help\\:\\ 0\\.020152556609031303\ \(0\)\
\-\ bright\\:\\ 0\\.01999717359632159\ \(0\)\
\-\ normally\\:\\ 0\\.01999717359632159\ \(0\)\
\-\ for\\:\\ 0\\.01994449583003574\ \(0\)\
\-\ on\\:\\ 0\\.019873746641708212\ \(0\)\
\-\ five\\:\\ 0\\.019811378697023072\ \(0\)\
\-\ six\\:\\ 0\\.01970406364822323\ \(0\)\
\-\ doppler\\:\\ 0\\.01963414887974523\ \(0\)\
\-\ again\\:\\ 0\\.019565482656235582\ \(0\)\
\-\ lumen\\:\\ 0\\.019531603967188553\ \(0\)\
\-\ markedly\\:\\ 0\\.01936654831342029\ \(0\)\
\-\ infections\\:\\ 0\\.01936654831342029\ \(0\)\
\-\ discussion\\:\\ 0\\.01920828703243526\ \(0\)\
\-\ degree\\:\\ 0\\.01917740167496131\ \(0\)\
\-\ major\\:\\ 0\\.01917740167496131\ \(0\)\
\-\ received\\:\\ 0\\.01908620673662779\ \(0\)\
\-\ that\\:\\ 0\\.019037462664114574\ \(0\)\
\-\ hemorrhagic\\:\\ 0\\.019026589940379625\ \(0\)\
\-\ regions\\:\\ 0\\.01882492242116045\ \(0\)\
\-\ numerous\\:\\ 0\\.018527951953010408\ \(0\)\
\-\ thickened\\:\\ 0\\.01850205820982353\ \(0\)\
\-\ necessary\\:\\ 0\\.01835025403586803\ \(0\)\
\-\ point\\:\\ 0\\.01813322554976239\ \(0\)\
\-\ development\\:\\ 0\\.01813322554976239\ \(0\)\
\-\ frequently\\:\\ 0\\.01806352201573565\ \(0\)\
\-\ absent\\:\\ 0\\.01799505956034732\ \(0\)\
\-\ total\\:\\ 0\\.01797250696588816\ \(0\)\
\-\ foci\\:\\ 0\\.017927794760554918\ \(0\)\
\-\ previously\\:\\ 0\\.017608064437695362\ \(0\)\
\-\ involved\\:\\ 0\\.017587665417267567\ \(0\)\
\-\ films\\:\\ 0\\.017370140743493325\ \(0\)\
\-\ especially\\:\\ 0\\.01735096261729153\ \(0\)\
\-\ many\\:\\ 0\\.01729399555561416\ \(0\)\
\-\ increasing\\:\\ 0\\.01727519255319516\ \(0\)\
\-\ considered\\:\\ 0\\.017092052877617635\ \(0\)\
\-\ failure\\:\\ 0\\.016653088331805975\ \(0\)\
\-\ rare\\:\\ 0\\.01655852931273758\ \(0\)\
\-\ classic\\:\\ 0\\.016405921731778197\ \(0\)\
\-\ since\\:\\ 0\\.015888727320303657\ \(0\)\
\-\ involvement\\:\\ 0\\.015875670579973956\ \(0\)\
\-\ above\\:\\ 0\\.01582388250648264\ \(0\)\
\-\ very\\:\\ 0\\.015734898554313766\ \(0\)\
\-\ vein\\:\\ 0\\.015722353008658107\ \(0\)\
\-\ later\\:\\ 0\\.01569738404863299\ \(0\)\
\-\ they\\:\\ 0\\.01567257617979371\ \(0\)\
\-\ quadrant\\:\\ 0\\.015363844493478832\ \(0\)\
\-\ obstruction\\:\\ 0\\.015363844493478832\ \(0\)\
\-\ because\\:\\ 0\\.015329765632312106\ \(0\)\
\-\ being\\:\\ 0\\.015284791946149654\ \(0\)\
\-\ heart\\:\\ 0\\.015251403548244414\ \(0\)\
\-\ liver\\:\\ 0\\.015131401555162514\ \(0\)\
\-\ given\\:\\ 0\\.015088676600796332\ \(0\)\
\-\ left\\:\\ 0\\.014964642671108554\ \(0\)\
\-\ inflammatory\\:\\ 0\\.014831891871584083\ \(0\)\
\-\ cases\\:\\ 0\\.014753214828454918\ \(0\)\
\-\ three\\:\\ 0\\.014724121073019866\ \(0\)\
\-\ initial\\:\\ 0\\.014714471867623863\ \(0\)\
\-\ study\\:\\ 0\\.014628701627578946\ \(0\)\
\-\ several\\:\\ 0\\.01439115493287057\ \(0\)\
\-\ further\\:\\ 0\\.014286279168370976\ \(0\)\
\-\ found\\:\\ 0\\.014192592873724617\ \(0\)\
\-\ any\\:\\ 0\\.014175801553013376\ \(0\)\
\-\ while\\:\\ 0\\.014175801553013376\ \(0\)\
\-\ onset\\:\\ 0\\.014084737513092915\ \(0\)\
\-\ tenderness\\:\\ 0\\.01375561888055736\ \(0\)\
\-\ changes\\:\\ 0\\.01325627053745127\ \(0\)\
\-\ infection\\:\\ 0\\.013249680636382488\ \(0\)\
\-\ syndrome\\:\\ 0\\.013223433392268445\ \(0\)\
\-\ abnormal\\:\\ 0\\.01317792746078263\ \(0\)\
\-\ likely\\:\\ 0\\.01310748873895077\ \(0\)\
\-\ edema\\:\\ 0\\.013082191237623322\ \(0\)\
\-\ she\\:\\ 0\\.013057059080622895\ \(0\)\
\-\ two\\:\\ 0\\.013025873132448818\ \(0\)\
\-\ however\\:\\ 0\\.01298263340881208\ \(0\)\
\-\ performed\\:\\ 0\\.012976495807616747\ \(0\)\
\-\ if\\:\\ 0\\.012744464022374412\ \(0\)\
\-\ fluid\\:\\ 0\\.012664471704276892\ \(0\)\
\-\ low\\:\\ 0\\.0125861096202092\ \(0\)\
\-\ cell\\:\\ 0\\.012547519411972175\ \(0\)\
\-\ metastatic\\:\\ 0\\.012029951867871829\ \(0\)\
\-\ abdominal\\:\\ 0\\.01199653583593556\ \(0\)\
\-\ increased\\:\\ 0\\.011861110808810115\ \(0\)\
\-\ upper\\:\\ 0\\.011721433593485556\ \(0\)\
\-\ without\\:\\ 0\\.011569600872129939\ \(0\)\
\-\ small\\:\\ 0\\.011314531133333711\ \(0\)\
\-\ case\\:\\ 0\\.011019632182223625\ \(0\)\
\-\ had\\:\\ 0\\.01092855245433887\ \(0\)\
\-\ female\\:\\ 0\\.010584386708347274\ \(0\)\
\-\ normal\\:\\ 0\\.008955691312300548\ \(0\)\
\-\ pain\\:\\ 0\\.007848955577138798\ \(0\)\
